1. LECT 22: LIPIDS, MEMBRANES, AND CHOLESTEROL Lipids and cholesterol in the body derive from food intake and from de novo synthesis. Phospholipids are principle constituent of cell membranes, and specialized phospholipids participate in signal transduction pathways. Lipid and cholesterol synthesis intermediate anchors serve to attach certain proteins to membranes. Cholesterol is a membrane constituent needed in all cells. Bile acids used for intestinal fat uptake and nuclear hormones are synthesized from cholesterol. Cholesterol is only synthesized in the liver, so that all other tissues must receive cholesterol by trafficking through blood in the form of lipoprotein particles.

2. Phospholipids Have Glycerol Backbone, Two Fatty Acids, and Phosphate Alcohol

3. The Four Common Phospholipids Phosphatidylinositol(PI) has diverse functions. In addition to being a major membrane constituent, PI’s inositol ring can be phosphorylated to generate a signal transduction intermediate. PI can also be further modified to generate the GPI membrane anchor.

4. Phospholipid Synthesis Uses CDP Intermediates

5. Sphingosine Is a Fatty Amine Used to Generate the Specialized Lipid Sphingomyelin

6. Fatty Acids Tend To Form Micelles, While Phospholipids Form Bilayer Membranes That Are Water Impermeable Fatty acids or other detergents can solubize membranes, dissolving them into mixed micelles

7. A Detergent’s “Strength” Reflects Types of Hydrophobic Interactions It Can Disrupt VERY WEAK DETERGENT: Disrupts only very weak hydrophobic interactions. Example: Tween-20. Useful in protein binding reactions (e.g., Western blot) to prevent nonspecific binding of antibody to filter or filter-bound proteins. MILD NONIONIC DETERGENT: Dissolves plasma membrane, other non-nuclear membranes, and incorporates constituents into detergent micelles. Examples: Triton X-100, Nonidet P40 STRONG IONIC DETERGENT: Solubilizes all membranes, disrupts protein-protein interactions, and denatures proteins. E.g. SDS

8. Sonicated Phospholipid Forms Small Lipid Vesicles, Liposomes, That Trap Aqueous Materials Inside

9. Lipophilic Protein Anchors Tether Proteins to Membranes

10. Some Proteins Contain Signal Motifs for Lipophilic Modification Lipophilic anchor attachments accompanied by peptide cleavage -C-A-A-X SH -C S C 15 Farnesylation (cytoplasmic) M-G-(6aa)- G-(6aa)- NH C 14 Myristoylation (cytoplasmic) GPI Anchoring (ER Lumen) 20aa hydrophobic tail GPI

11. Membrane Fluidity Demonstrated By Photobleach Recovery

12. This reaction catalyzed by HMG-CoA reductase is rate-limiting for cholesterol biosynthesis HMG-CoA Reductase Initiates the Cholesterol Synthetic Pathway

13. C5C5 C 10 C 15 C 30 Geranyl Isopentyl Farnesyl Squalene Cholesterol Is Built From Six Isopentenes and C30 Cyclization

14. Cholesterol Is The Precursor For Nuclear Hormones

15. Cholesterol Biosynthesis in Liver Regulated at the HMGCoAR Gene HMGCoAR gene transcription controlled by transcription factor SREBP. When cholesterol is abundant, its interaction with SCAP in the ER keeps SREBP tethered to ER as part of larger precursor. Decline in cholesterol allows SCAP/SREBP to move to Golgi, where proteases liberate SREBP, which goes to nucleus to activated transcription.

16. Lipoprotein Particles Employ Specific Apolipoproteins to Package Cholestero Estersl and Triglycerides in a Phospholipid/Cholesterol Shell

17. Lipoprotein Particles Are Taken Up By Cells By Specific Receptors That Recognize the Apolipoprotein Component After uptake, lysosomes degrade apolipoprotein, and cholesterols are incorporated into endoplasmic reticular membrane

18. Lipids and Cholesterol Are Shuttled Through an Organ Network EXCESS SERUM LDL INCREASES RISK OF CARDIOVASCULAR DISEASE

19. Genetic Causes of Cardiovascular Disease Hypercholesterolemia cause by mutations in genes for LDLR or LDL’s ApoB100, which prevent circulating LDL uptake Mutations in ApoE cause reduction in HDL production, thereby impairing circulating cholesterol trafficking back to liver

20. Clinical Management of Cardiovascular Disease or Risk Dietary management, including restricting cholesterol and reducing saturated fat and sugar intake Cholesterol reuptake inhibitors: Cholestyramines taken orally bind to bile acids in gut and prevent their reabsorption, thereby lowering total cholesterol load Statins (e.g., atorvistatin, lovastatin) inhibit HMG-CoA reductase, thereby blocking de novo cholesterol synthesis in liver